NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

AEK, As far as I know, the 3 major errors found to date in Reardon's
review article (Chen et al.) have only been presented here in separate posts.

1. The first error was the reviewers' claim that the mOS of the
entire trial of 331 patients was almost 4 months longer than the mOS
of the 232 patients in the treatment group when in fact the mOS of the entire
trial was only about 0.8 months longer than the mOS of the treatment
group; This error was committed because the reviewers were apparently
unaware of the fact that the mOS of all 331 patients in the trial was measured
from surgery whereas the mOS of the 232 treatment patients was measured
from randomization.

2. The second error is described in the post I am replying to (your post) and
that error stated that 90% of the 99 patient placebo group crossed over after
disease progression when in fact only 64 of those 99 did so.

3. The third error found by Senti deals with the review's claim that no
information concerning the IDH1 mutant status was presented in the trial
results when in fact that data was presented. It was reported that very few
(about 7?) GBM patients did carry that mutation.

4. In my opinion, the fourth reviewer error was the fact that Chen et al.
had the nerve to actually publish their blatant lies.